The verified answer
As of Oct 2026, DEPLOY verifies MicroPort MedBot: 2 models, 8 deployments across 8 regions. 3 sources back the record.
MicroPort MedBot holds 1 NMPA registration and 1 FDA 510(k) clearance, per the DEPLOY registry.
See all 2 filingsCategorySurgical robots
Overview
Shanghai MicroPort MedBot (Group) Co., Ltd. (HKEX: 02252) is a surgical robotics company spun out of MicroPort Scientific in 2015. Its flagship Toumai laparoscopic surgical robot has received regulatory approval in over 60 countries and achieved 100+ commercial orders, making it the leading Chinese-developed surgical robot globally. The company covers five surgical robotics subsectors: endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture.
Verified record
- Verified deployments
- 8 deployments on file
- Active incidents
- None on file
Key facts
CEO
Parent
Financial stage
Toumai orders
Countries
Data & sources
Press releases
1
Web sources
2
3 sources backing this record.View all →
Models (2)
View all models →Current platform
Toumai
The Toumai Endoscopic Surgical Robot is MicroPort MedBot's flagship laparoscopic surgical robotics system, featuring remote telesurgery capabilities. It became the world's first surgical robot to receive regulatory approval for commercial remote surgery in April 2025, and has been deployed in nearly 40 countries across six continents. Toumai has achieved 100+ commercial orders and 80+ installations worldwide, with notable deployments including Cleveland Clinic Abu Dhabi, Gemelli Hospital Italy, and AZ Delta Belgium.
Current platform
Toumai
MicroPort MedBot developed the Toumai, a four-arm laparoscopic surgical robot that became the first Chinese-developed surgical robot to receive NMPA regulatory clearance, granted in January 2022. The system uses 3D HD vision and wristed surgical instruments for minimally invasive procedures across urology, gynecology, and general surgery. A single-port variant, the Toumai SP, received separate NMPA clearance in March 2025, and a tele-operative version received NMPA approval in May 2025 as the first tele-surgical robot authorized for commercial clinical use globally.
Partnerships
Every company MicroPort MedBot has built with, alongside the ones only announced in a press release.
MicroPort MedBot on the deployment map
View the global map8 verified deployments across 8 regions, newest verified Jun 2025. Explore where MicroPort MedBot's robots are operating, by place and type.
- operationalToumai at Luanda, Angola →Africa · verified Jun 2025
- operationalToumai at Aalst, Belgium →Western Europe · verified May 2025
- operationalToumai at Sao Paulo, Brazil →São Paulo · verified Jan 2024
- operationalToumai at Bangkok, Thailand →Southeast Asia · verified Jan 2024
- operationalToumai at Mumbai, India →South Asia · verified Jan 2024
- operationalToumai at Casablanca, Morocco →Casablanca-Settat, Morocco · verified Jan 2024
- operationalToumai at Rome →Lazio, Italy · verified Jan 2024
- operationalToumai at Abu Dhabi →Middle East · verified Jan 2024
View the full MicroPort MedBot deployment record →
Relationships
Current leadership (1)
- Dr. Chao He Founder & PresidentSEC-verified
Founders (1)
- Dr. Chao Hesole
Safety record
No incidents on record for MicroPort MedBot.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Operator customers (1)
- MicroPort MedBot8 deployments
Recent coverage
MicroPort MedBot in third-party press
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
- Neocis2 models
Financial state
- Reporting basis
- private_reported
- Revenue disclosed
- $38000000 (private_reported)
- Lifecycle stage
- growth
- Counterparty risk class
- moderate
- SEC filing
- other
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Partnerships
2 total · 2 operating
Every company MicroPort MedBot has built with, alongside the ones only announced in a press release.
All 2 partnerships
open in the atlas →- microport-medbot x awswithAWS976technology—operating
- microport-medbot x nvidiawithNVIDIA1112technology—operating
Regulatory filings (2)
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJun 27, 2026
Added to the verified registry
- Deployment verifiedVerifiedJun 14, 2025
Toumai at Luanda, Angola
- Deployment verifiedVerifiedMay 26, 2025
Toumai at Aalst, Belgium
- Deployment verifiedVerifiedJan 1, 2024
Toumai at Mumbai, India
- Deployment verifiedVerifiedJan 1, 2024
Toumai at Casablanca, Morocco
Sources (3)
- https://www.medbotsurgical.com/en/news/53.html
- Toumai Surgical Robot Achieves Global Commercialization Milestone with 100 Orders · https://microport.com/news/toumai-surgical-robot-achieves-global-commercialization-milestone-with-100-orders
- MicroPort - Wikipedia · https://en.wikipedia.org/wiki/MicroPort
Common questions
What is MicroPort MedBot?
What does MicroPort MedBot make?
Is MicroPort MedBot publicly traded?
Who competes with MicroPort MedBot?
Who is the CEO of MicroPort MedBot?
How can I invest in MicroPort MedBot?
Where is MicroPort MedBot headquartered?
Who owns MicroPort MedBot?
Where does MicroPort MedBot operate robots?
How many robots has MicroPort MedBot deployed?
Is MicroPort MedBot a top robotics company?
When was MicroPort MedBot founded?
Is MicroPort MedBot safe?
Methodology: Verified · 3 sources (1 primary) · last reviewed 2026-08-21
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-08-21
Sources by quality tier
- 1
- unclassified
- Unclassified source
- 1
- primary-company-ir
- Company IR disclosure
- 1
- knowledge-base
- Knowledge base
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for MicroPort MedBot.Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
- Neocis2 models
In the press
Recent coverage mentioning MicroPort MedBot from third-party publications. Automatically surfaced; not part of the verified registry record.
Toumai Surgical Robot Achieves Global Commercialization Milestone with 100 Orders
MicroPort MedBot announces 100 cumulative global commercial orders for Toumai, with 80+ installations across nearly 40 countries.
Toumai Completes World's First FDA-IDE Approved USA-Africa Robotic Telesurgery
World's first FDA-IDE approved robotic telesurgery performed across 17,000 km from Orlando to Luanda, Angola.
Exclusive: Groundbreaking remote robotic surgery - patient in Africa, doctor in Florida
ABC News exclusive on the first FDA-IDE approved transcontinental telesurgery from Orlando to Angola using Toumai.
Toumai Robot Enables First-Ever Intra-EU Telesurgery Cases
First intra-European telesurgeries completed using CE-certified Toumai between Orsi Academy and AZORG Hospital in Belgium with 20ms latency.
MicroPort - Wikipedia
Wikipedia article on MicroPort Scientific, parent of MicroPort MedBot, covering its history and surgical robotics subsidiary.
Machine-readable surfaces
- Markdown mirror: /companies/microport-medbot.md
- RSS feed: /companies/microport-medbot/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/ebba8794-a39c-4a89-81f3-e05ff9b81428
- Revision history: /companies/microport-medbot/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- Koninklijke Philips2 models
- LEM Surgical2 models
- Neocis2 models
Video
The Medbot Toumai® Surgical Robot demonstrates exceptional control by suturing the delicate eggshell membrane between the eggshell and the egg white — a task th
Heat Index
Serious54/100
A composite of competitive footprint, funding, press velocity, active partnerships, and supply-chain edges. Different from the Intelligence score below (which is per-form-factor productization). Non-robotics companies cap at 25.
Reality vs attention
MicroPort MedBot draws attention at the 11th percentile but verifies reality at the 90th percentile among surgical robots. Hype Gap -78.7, 44th widest among surgical robots.
6-month trend
Analysis
Clean safety record across 8 verified deployments. Strong deployment footprint with 8 operational sites across 8 countries. Limited public funding data for capital position assessment.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Oct 3, 2026